|
China-India joint summit discusses bilateral trade to improve pharma industry
|
|
Shardul Nautiyal, Mumbai
May 30 , 2019
|
|
|
The China-India joint summit held recently discussed bilateral trade to
improve Indo- China pharma industry and address issues like long product
registration time and high fees for product registration in China’s
drug regulatory system, among other issues.
Besides this, other
relevant key issues related to transparency in public procurement system
in China and clinical trial related approvals were also deliberated at
the summit organised under the aegis of Indian Pharmaceutical
Association (IPA), Shengjie and SaSPinjara, China between May 16 and May
17, 2019 at Pullman Shanghai South, China.
The summit was focused on enhancing export business for both the nations across the globe.
Senior
health ministry official from Government of Gujarat Punamchand Parmar
was invited as the Chief Guest of the summit and Gujarat Food and Drugs
Control Administration (FDCA) Commissioner Dr Hemant Koshia was invited
as Guest of Honour. Among other dignitaries, Dr. Anil Kumar Rai,
Consulate General of India, Shanghai also attended the inauguration
ceremony.
Dr Koshia delivered a speech on “Regulatory Overview of
India- Feasibility for Import and Export” and discussed about
regulatory practices in India and Gujarat State. He advocated for a more
rationale policy on requirement and mandate for new clinical trial data
to get approvals in China.
During his address, Dr Koshia
pinpointed that clinical trials and bio-equivalence (BE) studies of
Indian pharma are accepted by US FDA-EU but not by China NMPA. There is
also a greater need for an accountable and transparent public
procurement policy in China, he said, adding that generating new
clinical trial data is time consuming and is capital intensive for an
Indian company.
“Added to it is the challenge of acceptance of
Indian firms having US FDA- EU-Japan approvals. Besides this, the other
grave concern is that Chinese companies are allowed for contract
manufacturing in India but Indian companies are not allowed to do so,”
explained Dr Koshia.
During the technical session, Parmar
delivered a keynote address on “India-China Pharmaceutical Cooperation
Feasibility: Overview on Policy and Acceleration Path” and discussed
various aspects related to India-China pharmaceutical trade and issues.
More than 800 delegates coming from pharmaceutical Industries and academicians from across the globe participated in the summit.
Exhibitors
of clinical research organisations (CROs), solution providers,
equipment manufacturers, representatives from API (bulk drugs),
biologicals, formulation industries attended the summit from India,
China and USA. During the summit Indian and Chinese participants
interacted and understood their current issues related to India-China
trade.
India is highly dependent on China as it sources more
than 80 per cent of its APIs from China. However on the other hand,
India’s exports to China is very less as compared to the latter.
However, of late, there is a slow surge in the Indian pharmaceutical
exports to China.
As per the statistics provided by Pharmexcil,
India’s pharmaceutical exports to China which stood at US$ 145.45
million in the year 2016-17 has shown a considerable growth of 37.52 per
cent and stood at US$ 200.02 million in the year 2017-18.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|